Megan Megan

Dr. Megan Megan

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in Drug and Alcohol Dependence Reports
Verified
Journal Article
Open access
MMMegan Megan
Megan Megan
NINicholas S. Imperato
Nicholas S. Imperato
JBJeanette M. Bowles
Jeanette M. Bowles
VSVenise J. Salcedo
Venise J. Salcedo
AGAmanda Guth
Amanda Guth
KRKristin L. Rising
Kristin L. Rising
Xylazine is an animal tranquilizer increasingly detected in those who have died of an opioid overdose in Philadelphia, PA and elsewhere. Despite an increasing presence of xylazine in the local fentanyl/heroin drug market and its association with ulcers, there are few perspectives about xylazine from people who use drugs and no data about the utility of a hypothetical xylazine test strip. Between January to May 2021 in Philadelphia, PA, people who used fentanyl/heroin and had previously used fentanyl test strips were queried about xylazine and hypothetical xylazine test strips. Interviews were transcribed and analysis was conducted via conventional content analysis. Participants (7 spontaneously, 6 after probing, n = 13) discussed "tranq" (i.e., xylazine) in the fentanyl/heroin supply. None enjoyed tranq or wanted it in their fentanyl/heroin. Participants suspected xylazine saturation of the fentanyl/heroin market, disliked the sensation of the drug, and had safety concerns about xylazine exposure. Participants did not indicate concerns about overdose. All were interested in hypothetical xylazine test strips. While previous literature indicates that some people enjoy tranq in their fentanyl/heroin, our findings differed, with participants expressing concern about the consequences of undesired exposure. The interest expressed for xylazine test strips by people who use fentanyl/heroin is an important opportunity to center their voices in the development of innovations designed to mitigate the harms of unwanted adulterant exposure. In the present study, people who use fentanyl/heroin indicated an interest to test their drug for the presence of xylazine prior to use.

12 February 2021 in International Journal of Drug Policy
Verified
Journal Article
Closed access
MMMegan Megan
Megan Megan
ARAlexis M. Roth
Alexis M. Roth
LTLoni P. Tabb
Loni P. Tabb
AGAli K. Groves
Ali K. Groves
SLStephen E. Lankenau
Stephen E. Lankenau

1 January 2017 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
SLStephen E. Lankenau
Stephen E. Lankenau
EFEkaterina V. Fedorova
Ekaterina V. Fedorova
MMMegan Megan
Megan Megan
SSSheree M. Schrager
Sheree M. Schrager
EIEllen Iverson
Ellen Iverson
CWCarolyn F. Wong
Carolyn F. Wong

4 March 2022 in International Journal of Drug Policy
Verified
Journal Article
Closed access
MMMegan Megan
Megan Megan
AGAmanda Guth
Amanda Guth
VSVenise J. Salcedo
Venise J. Salcedo
JHJeffrey K. Hom
Jeffrey K. Hom
KRKristin L. Rising
Kristin L. Rising

5 May 2022 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
MMMegan Megan
Megan Megan
VSVenise J. Salcedo
Venise J. Salcedo
AGAmanda Guth
Amanda Guth
KRKristin L. Rising
Kristin L. Rising

1 November 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
MMMegan Megan
Megan Megan
KWKarla D. Wagner
Karla D. Wagner
NNguyen Tran
Nguyen Tran
KBKathleen A. Brady
Kathleen A. Brady
JSJennifer Shinefeld
Jennifer Shinefeld
ARAlexis Roth
Alexis Roth